上海2026年8月21日 /美通社/ -- 劲方医药为原创型“全球新”药物开发企业,于2025 年9 月在香港联交所主板上市、录得2022 年以来港股18A板块最高募资额和基石认购额。劲方医药亦为IPO阶段首个同时拥有一类获批新药(氟泽雷塞)及授权收入的biotech。基于“全球新”产品一体化开发体系的研发能力和跑通产品上市的新药开发经验,公司的大、小分子平台不断优化升级、亦有更多款创新产品进入...
Source Link上海2026年8月21日 /美通社/ -- 劲方医药为原创型“全球新”药物开发企业,于2025 年9 月在香港联交所主板上市、录得2022 年以来港股18A板块最高募资额和基石认购额。劲方医药亦为IPO阶段首个同时拥有一类获批新药(氟泽雷塞)及授权收入的biotech。基于“全球新”产品一体化开发体系的研发能力和跑通产品上市的新药开发经验,公司的大、小分子平台不断优化升级、亦有更多款创新产品进入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.